Semimechanistic Population PK/PD Modeling of Axatilimab in Healthy Participants and Patients With Solid Tumors or Chronic Graft‐Versus‐Host Disease

Ähnliche Einträge

• Exposure‐Response Relationships for Axatilimab in Patients with Chronic Graft‐Versus‐Host Disease
  von: Yan‐ou Yang, et al.
  Veröffentlicht: (2025)
• Population Pharmacokinetics of siRNA JNJ ‐73763989 in Healthy Participants and Patients With Chronic Hepatitis B
  von: Tetsuro Ogawa, et al.
  Veröffentlicht: (2025)
• Machine Learning and Artificial Intelligence in PK‐PD Modeling: Fad, Friend, or Foe?
  von: Zhonghui Huang, et al.
  Veröffentlicht: (2024)
• Transforming the Discovery of Targeted Protein Degraders: The Translational Power of Predictive PK/PD Modeling
  von: Robin Thomas Ulrich Haid, et al.
  Veröffentlicht: (2024)
• Reinforcement Learning and PK‐PD Models Integration to Personalize the Adaptive Dosing Protocol of Erdafitinib in Patients with Metastatic Urothelial Carcinoma
  von: Alessandro De Carlo, et al.
  Veröffentlicht: (2024)